Evidence map›Paper›PMID 38451273›Full record

ArticleCancer chemotherapy and pharmacology2024

Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors.

Colby S Shemesh, Yongsheng Wang, Andrew An, Hao Ding, Phyllis Chan, Qi Liu, Yih-Wen Chen, Benjamin Wu, Qiong Wu, Xian Wang

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02794571 (A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Patients With Locally Advanced or Metastatic Tumors), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02794571 phase1completednot on this map

A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Patients With Locally Advanced or Metastatic Tumors

TypeinterventionalSponsorGenentech, Inc.Ran2016 to 2024Enrolled518ConditionsAdvanced/Metastatic TumorsArmsAtezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Colby S Shemesh *Clinical Pharmacology, Genentech Inc., South San Francisco, CA, USA. shemesh.colby@gene.com.
Yongsheng Wang *Clinical Trial Center, West China Hospital, Sichuan University, Chengdu, China.
Andrew AnSafety Science, F. Hoffmann-La Roche Ltd, Beijing, China.
Hao DingClinical Pharmacology, Genentech Inc., South San Francisco, CA, USA.
Phyllis ChanClinical Pharmacology, Genentech Inc., South San Francisco, CA, USA.
Qi LiuClinical Pharmacology, Genentech Inc., South San Francisco, CA, USA.
Yih-Wen ChenBioanalytical Science, Genentech Inc., South San Francisco, CA, USA.
Benjamin WuClinical Pharmacology, Genentech Inc., South San Francisco, CA, USA.
Qiong WuProduct Development Oncology, F. Hoffmann-La Roche Ltd, Shanghai, China.
Xian WangSir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, China.
Roche (China) · CNSichuan University · CNZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTiragolumab is an immunoglobulin G1 monoclonal antibody targeting the immune checkpoint T cell immunoreceptor with immunoglobulin and immunoreceptor ITIM domains. Targeting multiple immune pathways may improve anti-tumor responses. The phase I YP42514 study assessed the pharmacokinetics (PK), safety, and preliminary efficacy of tiragolumab plus atezolizumab in Chinese patients with advanced solid tumors.

methodsAdult patients from mainland China with Eastern Cooperative Oncology Group performance score 0/1, life expectancy of ≥ 12 weeks, and adequate hematologic/end organ function were eligible. Patients received tiragolumab 600 mg and atezolizumab 1200 mg intravenous every 3 weeks. Key endpoints were PK (serum concentrations of tiragolumab and atezolizumab) and safety. Results from this study were compared with the global phase I study, GO30103 (NCT02794571).

resultsIn this study, 20 patients received a median of five doses of tiragolumab plus atezolizumab. Median age was 57.5 years, 85.0% of patients were male and the most common tumor type was non-small cell lung cancer. Exposures in Chinese patients were comparable to the global GO30103 population: geometric mean ratio was 1.07 for Cycle 1 tiragolumab area under the concentration-time curve

conclusionIn this study, tiragolumab plus atezolizumab was tolerable and demonstrated preliminary anti-tumor activity. There were no meaningful differences in the PK or safety of tiragolumab plus atezolizumab between the Chinese and global populations. CLINICAL TRIAL REGISTRATION NUMBER: China Clinical Trial Registry Identifier CTR20210219/YP42514. Date of registration 16 March 2021.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsNeoplasmsAdultAgedChinaEast Asian PeopleFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedatezolizumabAdvanced solid tumorsCombination anti-TIGIT and anti-PD-L1 cancer immunotherapyEthnic sensitivity and population bridgingImmune check point inhibitorsPhase I clinical trials

Identifiers

PMID38451273
PMCPMC11258083
OpenAlexW4392559527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.